Skip to main content

Table 1 Percentages of radiolabeled metabolites in plasma after intravenous injection of [11C]CB184

From: Assessment of safety, efficacy, and dosimetry of a novel 18-kDa translocator protein ligand, [11C]CB184, in healthy human volunteers

Time (min) HM1 HM2 HM3 [11C]CB184 LM1
3 1.4 ± 1.1 1.1 ± 0.7 0.3 ± 0.4 96.1 ± 2.7 1.2 ± 1.0
10 6.4 ± 3.7 8.7 ± 5.6 0.7 ± 0.7 83.8 ± 8.9 0.5 ± 0.6
20 12.2 ± 2.5 20.6 ± 6.0 5.0 ± 2.7 61.6 ± 8.0 0.6 ± 0.4
30 14.9 ± 2.5 25.3 ± 3.5 6.7 ± 3.7 52.9 ± 4.9 0.3 ± 0.3
40 18.4 ± 6.0 26.4 ± 4.8 7.7 ± 3.8 47.0 ± 5.0 0.5 ± 0.4
60 24.0 ± 8.1 29.4 ± 7.2 9.4 ± 3.3 36.7 ± 5.7 0.5 ± 0.7
  1. Data are the mean ± SD for healthy male subjects (n = 5)
  2. HM hydrophilic metabolite, LM lipophilic metabolite